J Gynecol Oncol.  2010 Sep;21(3):174-180. 10.3802/jgo.2010.21.3.174.

Plasma levels of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in women with cervical neoplasia

• Lee SW
• Lee SY
• Lee SR
• Ju W
• Kim SC

• KMID: 1980854
• DOI: http://doi.org/10.3802/jgo.2010.21.3.174

Abstract

OBJECTIVE
The goal of this study was to investigate the relationship between plasma levels of insulin-like growth factors-1 (IGF-1) and IGF-binding protein-3 (IGFBP-3) and the risk for cervical intraepithelial neoplasia (CIN) and cervical cancer.
METHODS
Plasma levels of IGF-1 and IGFBP-3 of 44 cervical cancer patients, 82 CIN patients and 40 neoplasm-free patients were investigated. Then the associations of the plasma levels of IGF-1 and IGFBP-3 with cervical neoplasm or its clinicopathologic parameters were analyzed.
RESULTS
The mean IGF-1 concentrations were significantly different among the control, CIN, and cervical cancer groups; the levels were higher in the CIN group compared to the controls. According to the quartile category, the plasma IGF-1 level was significantly higher (p=0.0015) in the CIN group than in the controls. The IGFBP-3 level showed no association between the controls and CIN groups (p=0.842). Although the mean IGF-1/IGFBP-3 molar ratio had borderline significance (p=0.08) among the study population, the quartile comparison showed a significantly higher IGF-1/IGFBP-3 molar ratio in the CIN group compared to the control group (p=0.041).
CONCLUSION
Plasma levels of IGF-1 and the IGF-1/IGFBP-3 molar ratio might be useful for the development early detection of cervical lesions and used as an adjuvant diagnostic tool for cervical neoplasia after more larger scale research.

Keyword

IGF-1; IGFBP-3; IGF-1/IGFBP-3 molar ratio; Cervical neoplasia

MeSH Terms

Cervical Intraepithelial Neoplasia
Female
Humans
Insulin-Like Growth Factor Binding Protein 3
Insulin-Like Growth Factor I
Molar
Plasma
Uterine Cervical Neoplasms
Insulin-Like Growth Factor Binding Protein 3
Insulin-Like Growth Factor I

Figure

• 

  Fig. 1 Scatter plots showing inverse correlation of serum concentrations of insulin-like growth factors-1 (IGF-1) with age, separately among the control group (A) and the cervical intraepithelial neoplasia (CIN) group (B).

• 

  Fig. 2 Serum levels of insulin-like growth factors-1 (IGF-1), IGF-binding protein-3 (IGFBP-3), and IGF-1/IGFBP-3 molar ratio in the study population showing significantly increased levels of IGF-1 and IGF-1/IGFBP-3 molar ratio in the cervical intraepithelial neoplasia (CIN) group.

• 

  Fig. 3 Levels of insulin-like growth factors-1 (IGF-1) according to cancer stage (p-value=0.92). There was no statistical difference in serum IGF-1 between early and advanced stage cervical cancer.

Reference

1. Preston-Martin S, Pike MC, Ross RK, Jones PA, Henderson BE. Increased cell division as a cause of human cancer. Cancer Res. 1990. 50:7415–7421.

2. Kim K, Ryu SY. Major clinical research advances in gynecologic cancer 2009. J Gynecol Oncol. 2009. 20:203–209.

3. Sara VR, Hall K. Insulin-like growth factors and their binding proteins. Physiol Rev. 1990. 70:591–614.

4. Rosenfeld RG, Lamson G, Pham H, Oh Y, Conover C, De Leon DD, et al. Insulinlike growth factor-binding proteins. Recent Prog Horm Res. 1990. 46:99–159.

5. Baxter RC, Saunders H. Radioimmunoassay of insulin-like growth factor-binding protein-6 in human serum and other body fluids. J Endocrinol. 1992. 134:133–139.

6. Furlanetto RW, Harwell SE, Frick KK. Insulin-like growth factor-I induces cyclin-D1 expression in MG63 human osteosarcoma cells in vitro. Mol Endocrinol. 1994. 8:510–517.

7. Minshall C, Arkins S, Straza J, Conners J, Dantzer R, Freund GG, et al. IL-4 and insulin-like growth factor-I inhibit the decline in Bcl-2 and promote the survival of IL-3-deprived myeloid progenitors. J Immunol. 1997. 159:1225–1232.

8. LeRoith D, Werner H, Beitner-Johnson D, Roberts CT Jr. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev. 1995. 16:143–163.

9. Stewart CE, Rotwein P. Growth, differentiation, and survival: multiple physiological functions for insulin-like growth factors. Physiol Rev. 1996. 76:1005–1026.

10. Esposito DL, Blakesley VA, Koval AP, Scrimgeour AG, LeRoith D. Tyrosine residues in the C-terminal domain of the insulin-like growth factor-I receptor mediate mitogenic and tumorigenic signals. Endocrinology. 1997. 138:2979–2988.

11. Hongo A, D'Ambrosio C, Miura M, Morrione A, Baserga R. Mutational analysis of the mitogenic and transforming activities of the insulin-like growth factor I receptor. Oncogene. 1996. 12:1231–1238.

12. LeRoith D, Baserga R, Helman L, Roberts CT Jr. Insulin-like growth factors and cancer. Ann Intern Med. 1995. 122:54–59.

13. Hakam A, Yeatman TJ, Lu L, Mora L, Marcet G, Nicosia SV, et al. Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Hum Pathol. 1999. 30:1128–1133.

14. Xie Y, Skytting B, Nilsson G, Brodin B, Larsson O. Expression of insulin-like growth factor-1 receptor in synovial sarcoma: association with an aggressive phenotype. Cancer Res. 1999. 59:3588–3591.

15. Ferry RJ Jr, Katz LE, Grimberg A, Cohen P, Weinzimer SA. Cellular actions of insulin-like growth factor binding proteins. Horm Metab Res. 1999. 31:192–202.

16. Arany E, Afford S, Strain AJ, Winwood PJ, Arthur MJ, Hill DJ. Differential cellular synthesis of insulin-like growth factor binding protein-1 (IGFBP-1) and IGFBP-3 within human liver. J Clin Endocrinol Metab. 1994. 79:1871–1876.

17. Ballard FJ, Knowles SE, Walton PE, Edson K, Owens PC, Mohler MA, et al. Plasma clearance and tissue distribution of labelled insulin-like growth factor-I (IGF-I), IGF-II and des (1-3) IGF-I in rats. J Endocrinol. 1991. 128:197–204.

18. Pollak M. Insulin-like growth factor physiology and cancer risk. Eur J Cancer. 2000. 36:1224–1228.

19. Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr. 2001. 131:Suppl 11. 3109S–3120S.

20. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst. 2000. 92:1472–1489.

21. Sandhu MS, Dunger DB, Giovannucci EL. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst. 2002. 94:972–980.

22. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science. 1998. 279:563–566.

23. Wolk A, Mantzoros CS, Andersson SO, Bergstrom R, Signorello LB, Lagiou P, et al. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst. 1998. 90:911–915.

24. Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst. 1999. 91:151–156.

25. Steller MA, Delgado CH, Zou Z. Insulin-like growth factor II mediates epidermal growth factor-induced mitogenesis in cervical cancer cells. Proc Natl Acad Sci U S A. 1995. 92:11970–11974.

26. Wu X, Tortolero-Luna G, Zhao H, Phatak D, Spitz MR, Follen M. Serum levels of insulin-like growth factor I and risk of squamous intraepithelial lesions of the cervix. Clin Cancer Res. 2003. 9:3356–3361.

27. Rinderknecht E, Humbel RE. The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. J Biol Chem. 1978. 253:2769–2776.

28. Macaulay VM. Insulin-like growth factors and cancer. Br J Cancer. 1992. 65:311–320.

29. Rogler CE, Yang D, Rossetti L, Donohoe J, Alt E, Chang CJ, et al. Altered body composition and increased frequency of diverse malignancies in insulin-like growth factor-II transgenic mice. J Biol Chem. 1994. 269:13779–13784.

30. Steller MA, Delgado CH, Bartels CJ, Woodworth CD, Zou Z. Overexpression of the insulin-like growth factor-1 receptor and autocrine stimulation in human cervical cancer cells. Cancer Res. 1996. 56:1761–1765.

31. Serrano ML, Romero A, Cendales R, Sanchez-Gomez M, Bravo MM. Serum levels of insulin-like growth factor-I and -II and insulin-like growth factor binding protein 3 in women with squamous intraepithelial lesions and cervical cancer. Biomedica. 2006. 26:258–268.

32. Bustin SA, Jenkins PJ. The growth hormone-insulin-like growth factor-I axis and colorectal cancer. Trends Mol Med. 2001. 7:447–454.

33. Gomez JM, Mourot B, Fostier A, Le Gac F. Growth hormone receptors in ovary and liver during gametogenesis in female rainbow trout (Oncorhynchus mykiss). J Reprod Fertil. 1999. 115:275–285.

34. Mathur RS, Mathur SP. In vitro downregulation of growth factors by insulin-like growth factor binding protein-3 in cervical cancer. Gynecol Oncol. 2003. 91:410–415.

35. Conover CA, Powell DR. Insulin-like growth factor (IGF)-binding protein-3 blocks IGF-I-induced receptor down-regulation and cell desensitization in cultured bovine fibroblasts. Endocrinology. 1991. 129:710–716.

36. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999. 189:12–19.

37. Dassonville O, Formento JL, Francoual M, Ramaioli A, Santini J, Schneider M, et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol. 1993. 11:1873–1878.

38. Nakamura K, Hongo A, Kodama J, Miyagi Y, Yoshinouchi M, Kudo T. Down-regulation of the insulin-like growth factor I receptor by antisense RNA can reverse the transformed phenotype of human cervical cancer cell lines. Cancer Res. 2000. 60:760–765.

39. Berger AJ, Baege A, Guillemette T, Deeds J, Meyer R, Disbrow G, et al. Insulin-like growth factor-binding protein 3 expression increases during immortalization of cervical keratinocytes by human papillomavirus type 16 E6 and E7 proteins. Am J Pathol. 2002. 161:603–610.